Multicentric Prevalence Study of Anti-P Ribosomal Autoantibodies in Juvenile Onset Systemic Lupus Erythematosus Compared With Adult Onset Systemic Lupus Erythematosus

Pisoni, Cecilia; Muñoz, Sebastián Andrés; Carrizo, Carolina; Cosatti, M.; Álvarez, Analía; Dubinsky, Diana; Bresan, Eleonora; Russo, Ricardo; Borgia, Ezequiel; Garcı́a, Marı́a Guadalupe; Sansinanea, Pierina; Basta, María Cristina; D’Amico, Maria Agustina; Barreira, Juan Carlos; Lancioni, Eliana; Soriano, Enrique R.; Cunto, Carmen De; Beron, A.; Eimon, Alicia

doi:10.1016/j.reumae.2014.03.015

Cited by 6 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding was relatively close to the result of a study done by Pisoni et al (12), 2015, where percentage of lupus nephritis was 66.7% and higher than a study done by Youssef et al (13), 2015, where percentage of lupus nephritis was 50%.…”

Section: Discussionsupporting

confidence: 86%

Level of Interleukin 37 (IL-37) in Children with Systemic Lupus Erythematosus and Its Correlation with Disease Activity

et al. 2017

View full text Add to dashboard Cite

Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by auto-antibodies against self-antigens. Interleukin 37 (IL-37) is a member of IL-1family, and it is a key cytokine in regulating inflammation. We aimed to detect the level of IL-37 in SLE patients and to correlate it with disease activity. Methods: A cross-sectional study included fifty children with SLE following up at the pediatric rheumatology clinic in specialized children's hospital, Cairo University and chosen randomly; aged up to 16 years and thirty, apparently healthy children with matched age and gender, were assigned as the control group. In all cases and controls, full history was taken, full physical examination performed and laboratory investigations including level of IL-37 were done. Results: Levels of IL-37 in the 50 cases with SLE were higher than in the 30 controls with statistically significant difference (P = 0.028). Level of IL-37 was higher in active cases than in inactive cases but without statistically significant difference (P = 0.58). Level of IL-37 level in cases with mild activity was lower than in cases with moderate or severe activity but without statistically significant difference (P = 0.23). Conclusions: level of IL-37 was higher in our SLE patients than in controls and it is higher in active cases than inactive cases. IL-37 is correlated positively with duration between onset and diagnosis of disease and SLEDAI-2K activity score.

show abstract

Section: Discussionsupporting

confidence: 86%

Level of Interleukin 37 (IL-37) in Children with Systemic Lupus Erythematosus and Its Correlation with Disease Activity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The frequency of anti-P autoantibodies in cSLE patients observed in the present study was similar to that reported for pediatric SLE populations. 4,7–9,26–30…”

Section: Discussionmentioning

confidence: 99%

Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients

Valões

Molinari

Pitta

et al. 2017

Lupus

View full text Add to dashboard Cite

Objectives Anti-ribosomal P protein (anti-P) autoantibodies are highly specific for systemic lupus erythematosus (SLE). However, the evaluation of this autoantibody in childhood-onset SLE (cSLE) populations has been limited to a few small series, hampering the interpretation of the clinical and laboratorial associations. Therefore, the objective of this multicenter cohort study was to evaluate demographic, clinical/laboratorial features, and disease damage score in cSLE patients with and without the presence of anti-P antibody. Methods This was a retrospective multicenter study performed in 10 pediatric rheumatology services of São Paulo state, Brazil. Anti-P antibodies were measured by ELISA in 228 cSLE patients. Results Anti-P antibodies were observed in 61/228 (27%) cSLE patients. Frequencies of cumulative lymphadenopathy (29% vs. 15%, p = 0.014), acute confusional state (13% vs. 5%, p = 0.041), mood disorder (18% vs. 8%, p = 0.041), autoimmune hemolytic anemia (34% vs. 15%, p = 0.001), as well as presence of anti-Sm (67% vs. 40%, p = 0.001), anti-RNP (39% vs. 21%, p = 0.012) and anti-Ro/SSA antibodies (43% vs. 25%, p = 0.016) were significantly higher in cSLE patients with anti-P antibodies compared to those without these autoantibodies. A multiple regression model revealed that anti-P antibodies were associated with autoimmune hemolytic anemia (odds ratio (OR) = 2.758, 95% confidence interval (CI): 1.304-5.833, p = 0.008) and anti-Sm antibody (OR = 2.719, 95% CI: 1.365-5.418, p = 0.004). The SLICC/ACR damage index was comparable in patients with and without anti-P antibodies ( p = 0.780). Conclusions The novel association of anti-P antibodies and autoimmune hemolytic anemia was evidenced in cSLE patients and further studies are necessary to determine if anti-P titers may vary with this hematological manifestation.

show abstract

“…32 In fact, the positivity of anti-P antibodies is associated with a younger mean age among SLE patients being more prevalent in juvenile-onset SLE (26.7–42%) than in adult-onset SLE (6.5%–7.7%). 33,37,38…”

Section: Diagnostic Biomarkers Frequently Used In Clinical Practicementioning

confidence: 99%

Systemic lupus erythematosus: The search for the ideal biomarker

González

Ugarte‐Gil

Alarcón

2020

Lupus

View full text Add to dashboard Cite

During the last decades, there has been an increased interest in the discovery and validation of biomarkers that reliably reflect specific aspects of lupus. Although many biomarkers have been developed, few of them have been validated and used in clinical practice, but with unsatisfactory performances. Thus, there is still a need to rigorously validate many of these novel promising biomarkers in large-scale longitudinal studies and also identify better biomarkers not only for lupus diagnosis but also for monitoring and predicting upcoming flares and response to treatment. Besides serological biomarkers, urinary and cerebrospinal fluid biomarkers have emerged for assessing both renal and central nervous system involvement in systemic lupus erythematosus, respectively. Also, novel omics techniques help us to understand the molecular basis of the disease and also allow the identification of novel biomarkers which may be potentially useful for guiding new therapeutic targets.

show abstract

Multicentric Prevalence Study of Anti-P Ribosomal Autoantibodies in Juvenile Onset Systemic Lupus Erythematosus Compared With Adult Onset Systemic Lupus Erythematosus

Cited by 6 publications

References 29 publications

Level of Interleukin 37 (IL-37) in Children with Systemic Lupus Erythematosus and Its Correlation with Disease Activity

Level of Interleukin 37 (IL-37) in Children with Systemic Lupus Erythematosus and Its Correlation with Disease Activity

Anti-ribosomal P antibody: a multicenter study in childhood-onset systemic lupus erythematosus patients

Systemic lupus erythematosus: The search for the ideal biomarker

Contact Info

Product

Resources

About